Potential therapeutic targets shared between leishmaniasis and cancer

Sajad Rashidi1, Celia Fernández-Rubio2, Raúl Manzano-Román3, Reza Mansouri4, Reza Shafiei5, Mohammad Ali-Hassanzadeh6, Afshin Barazesh7, Mohammadreza Karimazar1, Gholamreza Hatam6 and Paul Nguewa2

1Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; 2Department of Microbiology and Parasitology, IDISNA (Navarra Institute for Health Research), c/Irunlarrea 1, University of Navarra, ISTUN Instituto de Salud Tropical, 31008 Pamplona, Spain; 3Proteomics Unit, Cancer Research Centre (IBMCC/CSIC/USAL/IBSAL), 37007 Salamanca, Spain; 4Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran; 5Vector-borne Diseases Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran; 6Department of Immunology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran; 7Department of Microbiology and Parasitology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran and 8Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

The association of leishmaniasis and malignancies in human and animal models has been highlighted in recent years. The misdiagnosis of coexistence of leishmaniasis and cancer and the use of common drugs in the treatment of such diseases prompt us to further survey the molecular biology of Leishmania parasites and cancer cells. The information regarding common expressed proteins, as possible therapeutic targets, in Leishmania parasites and cancer cells is scarce. Therefore, the current study reviews proteins, and investigates the regulation and functions of several key proteins in Leishmania parasites and cancer cells. The up- and down-regulations of such proteins were mostly related to survival, development, pathogenicity, metabolic pathways and vital signalling in Leishmania parasites and cancer cells. The presence of common expressed proteins in Leishmania parasites and cancer cells reveals valuable information regarding the possible shared mechanisms of pathogenicity and opportunities for therapeutic targeting in leishmaniasis and cancers in the future.

Introduction

Leishmaniasis and cancer

Leishmaniasis is a group of vector-borne diseases caused by intracellular protozoan belonging to the genus Leishmania. Annually, approximately 1.5–2 million new cases are reported worldwide being 310 million people at risk. The mortality rate of the disease varies from 40 000 to 70 000 cases per year (Torres-Guerrero et al., 2017). Clinical manifestations vary depending on the Leishmania species and the immune status of the host, among others. The clinical symptoms of cutaneous leishmaniasis (CL) are mostly restricted to the skin lesions with diverse appearances, from localized to body extended wounds or mucosal affectations. However, visceral leishmaniasis (VL) is characterized by severe organic symptoms and might lead to death (Den Boer et al., 2011; Torres-Guerrero et al., 2017). Malnutrition, acquired immune deficiency syndrome and cancer are important factors that affect the host immune system and lead to more severe clinical symptoms in patients with leishmaniasis (Ezra et al., 2010; Nweze et al., 2020).

Cancer is a group of diseases involving an abnormal growth of cells, which tend to proliferate in an uncontrolled way and, in some cases, metastasize. It can affect almost any tissue of the body. After coronary artery diseases, cancer is the second major cause of death in humans. Each year, the global mortality rate of cancers is estimated at 8.2 million deaths and approximately 14.1 million new cases are being reported (Torre et al., 2016). The clinical manifestations of cancers are wide-ranging and the immunosuppression is a critical side-effect to be considered during the management of cancers (Blagosklonny, 2013).

The possible association of leishmaniasis and malignancies (cancers)

Although smoking is one of the principal causes of cancer development, infections are also a risk factor, mainly those caused by bacteria (Helicobacter pylori) (Nguewa et al., 2016) and viruses (Human papillomavirus, Hepatitis B and C viruses, Herpes virus, Epstein–Bar virus and human T-cell leukaemia–lymphoma virus) (Liao, 2006). However, certain parasitic infections (by Opisthorchis, Clonorchis, Theileria and Schistosoma) can also raise the risk of developing some types of cancers and may contribute to the appearance of malignancies which makes them possible models to study host–parasite interactions and mechanisms of cancer (De Martel et al., 2012; Tretina et al., 2015; Cheeseman and Weitzman, 2017).
The association of leishmaniasis and malignancies in human and animal models has been highlighted in previous studies (Kopterides et al., 2007; Ferro et al., 2013; Al-Kamel, 2017). Due to the relatively similar clinical manifestations in certain leishmaniasis forms and cancers, misdiagnosis might occur in the clinic (Toogeh et al., 2010; Schwing et al., 2019). For instance, the diagnosis of childhood leukaemia should be carefully differentiated from VL, especially in endemic areas where the concurrent occurrence has been reported (Vasconcelos et al., 2014). Similarly, cutaneous and mucocutaneous leishmaniasis may be clinically misdiagnosed as squamous cell carcinoma (SCC) (Ramos et al., 2015).

In addition, numerous compounds with anti-tumour activity have exhibited potent leishmanicidal properties (Table 1). The use of common drugs for the treatment of leishmaniasis and cancer might further propose and highlight the presence of plausible associations in clinical manifestations of leishmaniasis and tumoural alterations. Moreover, failures at epigenetic level to maintain integrity of chromosomes is one contributing factor in cancer and Leishmania parasites also modulate and destabilize the host chromatin structure leading to potential changes in relevant immune-related genes and responses (Sarkar et al., 2015; Afrin et al., 2019; Dacher et al., 2019).

Moreover, a set of compounds described as antitumour drugs also exhibited leishmanicidal activities. Alkylating antineoplastic agents such as cisplatin are inducers of cell death in both, tumour cells and parasites (Fuertes et al., 2003; Nguema et al., 2005). Miltefosine (hexadecylphosphocholine, HePC), an alkyl phospholipids compound, has been originally considered for breast cancer and other solid tumours’ treatment. Two compounds of the alkylphospholipid group, octadecyl-phosphocholine and hexadecylphosphocholine-miltefosine (HePC), have been found to have antineoplastic activity. The mechanism of antitumour action of these compounds was involved in the inhibition of substrate phosphorylation by protein kinase C (PKC) [triggering programmed cell death (apoptosis)]. The presence of PKC on Leishmania membrane led to the furthert investigations on such compounds against CL. It has been indicated that miltefosine inhibits the biosynthesis of the glycosyl phosphatidylinositol receptor, a vital molecule for Leishmania intracellular survival. Moreover, this compound interferes with the synthesis of leishmanial-phospholipase (PL) and PKC. The metabolic action of miltefosine affects the biosynthesis of glycolipids and membrane glycoproteins of the Leishmania parasite, leading to apoptosis (Sundar and Olliaro, 2007; Perez et al., 2008; dos Santos Nogueira et al., 2019; Fernández-Rubio et al., 2019). Another example is tamoxifen (as a triphenylethylene), a breast cancer drug that has shown an appropriate efficacy in the treatment of leishmaniasis (Miguel et al., 2007, 2008). Due to the activity of tamoxifen as an oestrogen receptor modulator, this drug has been used in the prevention and treatment of breast cancer. However, it has been elucidated that many biological effects of tamoxifen are independent of the oestrogen machinery, including modulation of calmodulin, kinases and caspases, inhibition of the acidification of intracellular organelles, interference in ceramide metabolism, and partitioning into lipids where it exerts membrane fluidizing and antioxidant activities. Oestrogen receptor-modulated responses are not present in Leishmania parasites. On the other hand, tamoxifen is able to inhibit the acidification of organelles in different cell types in an oestrogen-independent pathway. It seems that tamoxifen modifies the intravascular pH of Leishmania-infected macrophages inducing a condition where the drug activity against the Leishmania is increased (Miguel et al., 2007, 2008). In addition, camptothecin and its analogues target topoisomerase IB (TOP IB) and inhibit in Leishmania the activity of this relaxing enzyme for supercoiled DNA. Similarly, indenoisoquinolines, which are also TOP IB poisons, initially developed as antitumour compounds (Antony et al., 2005), are able to decrease parasite burden ‘in vitro’ and ‘in vivo’ in a mouse model (Balazs-Fouque et al., 2012). Furthermore, quinone derivatives that act as antitumour agents, showed anti-leishmanial activity through different mechanisms of action, including TOP II and trypanothione reductase inhibition (Sajad Rashidi et al., 2019; Mukherjee et al., 2004; Singh and Dey, 2007; Shukla et al., 2011).

**Drugs for the treatment of leishmaniasis and cancer with common signalling processes**

Drug repurposing is an extensively strategy used to identify new microbicial compounds including leishmanicidal agents. The effect of antitumour chemical compounds in leishmaniasis treatment might suggest the existence of possible similar mechanisms of pathogenicity and common therapeutic targets in Leishmania parasites and cancer cells. Selenocompounds have exhibited potent leishmanicidal properties blocking the mammalian target of rapamycin (mTOR) pathway (Ibanez et al., 2012) and reduced Leishmania parasite burden during ‘in vitro’ assays. Furthermore, these compounds were able to reduce the expression of leishmanial genes involved in cell cycle, resistance to treatment and virulence at the mRNA level (Fernández-Rubio et al., 2015). Similarly, naphtalimide derivatives which were previously synthesized as antitumour agents (Karelia et al., 2017), decreased intracellular amastigotes burden, caused cell cycle arrest and diminished the topoisomerase-2 (TOP II), mini-chromosome maintenance complex (MCM4) and proliferating cell nuclear antigen (PCNA) mRNA levels (Fernández-Rubio et al., 2019). Anti-cancer and anti-leishmaniasis effects of herbal compounds such as pentacylic triterpenoid are well known (Moulisha et al., 2010). Fatty acids from natural sources are inhibitors of therapeutic targets in cancer cells and Leishmania parasites (Carballeira et al., 2011, 2018; Carballeira, 2013).

Investigations have indicated the effect of Leishmania parasites on the immune system of patients with cancer thus triggering the modulation of anti-cancer immunity. In 2011, Kumar
**Table 1.** Some common compounds used against cancer and leishmaniasis

| Anti-leishmaniasis and -cancer drugs | Possible drug action in leishmaniasis (or protozoan parasites) | Possible drug action in cancer | References |
|-------------------------------------|---------------------------------------------------------------|--------------------------------|------------|
| Dichloroacetic acid (DCA)           | Switching infected-cell metabolism from aerobic glycolysis to oxidative phosphorylation by restoring mitochondrial activity | Inhibition of pyruvate dehydrogenase kinase (PDH) (leading to pyruvate dehydrogenase (PDH) activation and fostering oxidative phosphorylation/the increase of each Krebs cycle intermediate concentration/inducing cell toxicity through de novo synthesis of CoA/modulating intracellular acidification/inhibition of Na-K-2Cl cotransporter | Tataranni and Piccoli (2019); Martínez-Flórez et al. (2020) |
| 3-Bromopyruvic acid (3BP)          | Blocking early stages of the glycolytic cycle (inhibition of HK II or GAPDH activity) | Inducing cell death by necroptosis and apoptosis | Sun et al. (2015); Martínez-Flórez et al. (2020) |
| Diospyrin                          | Inhibitor of type I DNA TOP of the parasite Promoting apoptotic death of the infected cell | Targeting several genes and pathways in the cell (affecting cell proliferation and survival)/targeting cell transcriptional level (possible targeting of TOPs) | Ray et al. (1998); Sagar et al. (2010) |
| Modified lapachones                | Inhibition of serine proteinase activity in parasite | Nicotinamide adenine dinucleotide (NAD+ depletion) | Souza-Silva et al. (2015); Silvers et al. (2017) |
| 4-Substituted quinoline derivatives | Inhibitory activity against cysteine proteases type B | The occurrence of caspase-dependent apoptosis with involvement of mitochondrial permeabilization/inhibition of cysteine proteases activity | Costa et al. (2020) |
| DL-α-difluoromethylornithine (DFMO) | Inhibitor of ornithine decarboxylase | | Scheoncher et al. (1987); Keithly and Fairlamb (1988) |
| 17-N-Alllylamo-17-demethoxygeldanamycin (17-AAG, tanesipimycin) | Inhibitor of heat shock protein 90 (HSP90) | | Petersen et al. (2018); Pires et al. (2020) |
| Gold(II) complexes with 1,3,4-oxadiazole-2(3H)-thione ligands derived from d-D gluconolactone | Acting as anti-inflammatory agents and help immune response to tackle both tumour cells and Leishmania parasites | | Espinosa et al. (2020) |

et al. highlighted the role of *Leishmania* in mutual modulation of the immune system in a patient with Hodgkin’s lymphoma (Kumar et al., 2011). It’s clear that in both diseases the host immune response is critical for the disease outcome. In this sense, immune checkpoints are essential for the regulation of the immune system homeostasis and metastasis in cancer (Safarzadeh et al., 2020). These are also important factors regulating the function of T-cells and can be differentially modulated during pathogen infections (Cai et al., 2020). Leishmaniasis shares several key immunoregulatory features with cancer. Thus, in some forms of leishmaniasis, a number of important immune checkpoint molecules have also been identified (Kumar et al., 2017). Cytotoxic T-lymphocyte-associated protein 4 is one of the differentially induced immune checkpoints upon infection that may be targeted to ameliorate disease progression (Viana et al., 2019). These authors state that some *Leishmania* species induce a more inflammatory profile which also is well-established in cancer progression. Pattern recognition receptor expression and activation have pro-inflammatory effects on the tumour microenvironment via Toll-like receptor (TLR) signalling (McCall et al., 2020). *Leishmania* infections have differential capacities to activate TLRS and are able to block the TLR-based pro-inflammatory downstream signals. Parasite-derived microvesicles can activate specific TLR-based downstream immune inhibitory signals via CD200 to evade macrophage defenses and favour infection (Saha et al., 2019; Sauter et al., 2019).

Another shared mechanism is type I IFN-driven immunity. IFNs play essential roles in context-specific anti-pathogen responses and act in many immune-related processes in cancer including therapy (Silva-Barrios and Stager, 2017; Spooren et al., 2019). Recently, it has been discovered that type I IFNs are involved in the negative regulation of CD4+ T cell responses in patients with VL in order to thus promote their persistence by suppressing anti-parasitic immunity (Kumar et al., 2020). It seems that the action of IFNs may be by targeting DCs to suppress consequently priming and/or expansion of Th1 specific cells during the infection. These authors have also stated with animal models the potential of targeting type I IFN signalling to strength protective immunity. In this regard, some molecules of *Leishmania major* are able to affect DC maturation thus potentially enhancing DC-based vaccines for cancer (Arab et al., 2019). Furthermore, live attenuated non-pathogenic *Leishmania* parasites directly may induce immune-stimulant responses to regress breast cancer grown (Caner et al., 2020). Interestingly, these attenuated parasites led to a higher percentage of CD4+ and CD8+ T-cells secreting pro-inflammatory cytokines tumour necrosis factor-α (TNF-α), interleukin-12 (IL-12), IFN-γ, inducible nitric oxide synthase and IL-2, and finally, inducing tumour cell death. Cancer therapy is an essential research area and protein
### Table 2. Possible functions of several common proteins expressed in *Leishmania* parasites and cancer cells and plausible inhibitors/drugs against such proteins

| Cells | Proteins and possible functions | Inhibitor | SODs (Fe-SOD) | TOPs |
|-------|--------------------------------|-----------|---------------|------|
| Leishmania | HSP60 | HSP90 | PDI | PL | ALDH | VDAC-1 | PCNA | Tubulins | (Fe-SOD) | TOP IB | TOP II |
| HSP60 | Pathogenicity | Survival and proliferation | Pathogenicity and survival | PLC: pathogenicity | PLA2: virulence | Virulence and protective function against oxidative stress | Survival and adaptation to the environmental stresses | Pathology of the parasite (significant role in drug response) | Involved in parasite shape, replication, motility and pathology (drug resistance strains) | Protection against radical superoxide anions | Cut one DNA strand and covalently join to 3’ end | Catalyse topological changes in the DNA |
| HSP90 | Pathogenicity and survival | Bacitracin | PLA2: BEL | Gossypol | Ion channel blockers: verapamil, nifedipine, and ZINC295902E2 | Selenocompounds, selenocompounds, synthetic selenium derivatives | 2-Methoxyestradiol, reducible selenocompounds, natural alkaloids and marine fatty acids | Camptothecins, indenoisoquinolines, natural alkaloids and marine fatty acids | Isobenzofuranone derivatives, probioterberine, mithonafide |
| Cancer | Survival in neuroblastoma cells, anti-tumour in human hepatoma HuH-7 cells | Tumour initiation, development and metastasis | Survival, progression and metastasis | PI-PLC-δ1: progression of MDS PLCγ1: development of OPL | Pathogenicity and drug resistance | Survival and apoptosis | DNA replication and repair that is often overexpressed in cancer cells | Cell cycle promotion and drug resistance in cancers | Anti-tumour in brain malignant tumours | Progression and metastasis of pancreatic cancer | TOP IB: cut one DNA strand and covalently join to 3’ end | TOP II: catalyse topological changes in the DNA |
| Epolaetane, bortezomib, simularin and myrtucommulone | Epolaetane, bortezomib, simularin and myrtucommulone | PACMA, 16F16, bacitracin and RB-11-ca | Phosphatidylycholine-specific PLC inhibitor: D609 | DEAB, Gossypol in combination with phenformin | Ion channel blockers: verapamil and nifedipine | A cell-penetrating AK2 homologue 2 PCNA-interacting motif (APIM)-containing peptide: ATX-101 | Microtubule destabilizing tubulin inhibitors: colchicine analogues and vinca alkaloids | Microtubule-stabilizing tubulin inhibitors: taxanes (paclitaxel derivatives) | Camptothecins (irinotecan, topotecan and belotecan) | Etoposide: anthracycline and podophyllotoxin derivatives |
kinases are major targets for drugs. The mTOR is a highly conserved serine/threonine protein kinase that is central regulating essential cellular processes and mTOR inhibitors are used in cancer therapy (Chen and Zhou, 2020). Leishmania infection activates this key host protein kinase pathway via its phosphorylation which have important effect towards host cellular physiology (M2 macrophage phenotype polarization) and parasite survival inside macrophages through down-regulation of the nuclear factor-κB and signal transducer and activator of transcription 3 oncogene factors (Kumar et al., 2018). Another type of immune-related molecules which regulate diverse cellular processes involved in cancer and leishmaniasis are Ras, small cellular GTPases. Ras mutations are frequently observed in cancers and leukemia leading to different isoforms. Currently, research data demonstrate that these isoforms are differentially activated by CD40 to modulate effector signals like inflammation playing crucial roles in infectious diseases and tumour regression between others (Nair et al., 2020). Leishmania infections are able to inhibit CD40-induced N-Ras activation as a survival strategy switching CD40 signalling leading to inhibition of the p38MAPK pathway, the master regulator of transcript stability and tumour progression (Chakraborty et al., 2015; Soni et al., 2019).

From potential targets to drug repurposing

Novel shared targets may be identified by analysing proteins that play key roles in each disease. To date, mass spectrometry and functional proteomics along with other integrative-omics and multi-platforms allow shedding some light on the role of these molecules in different diseases (Cowell and Winzeler, 2019; Khan et al., 2020; Syu et al., 2020). In addition, some biomarkers of diseases seem to have high potential as drug targets, opening avenue for therapeutic screenings (Sharma et al., 2019; Roy et al., 2020). Accordingly, we therefore present some functional proteins that may be useful as shared/interchangeable therapeutic targets for the development pipeline of repurposed drugs against leishmaniasis and cancer.

Protein disulphide isomerases (PDIs)

PDIs belong to a group of multifunctional proteins which are located in the endoplasmic reticulum and catalyse the formation of disulphide bonds during protein creation (Ben Khalaf et al., 2012). In Leishmania parasites, it has been reported the role of these proteins in pathogenicity and survival. Moreover, their potential immunomodulatory property suggests such proteins as possible drug and vaccine targets against leishmaniasis (Achour et al., 2002; Gupta et al., 2007; Ben Khalaf et al., 2012; Jaiswal et al., 2014; Amit et al., 2017).

On the other hand, the expression of PDIs can affect the survival, progression and metastasis of cancer. In fact, PDI gene is up-regulated in different cancer types such as lymphoma, brain, ovarian or kidney among others (Xu et al., 2014). PDI inhibitor developments from natural and synthetic compounds have demonstrated their effectiveness and cytotoxicity against tumours and Leishmania parasites (Ben Khalaf et al., 2012; Xu et al., 2014; Lee, 2017). For instance, propynoic acid carbamoyl methyl amides (PACMA) 31, a new irreversible PDI inhibitor, and 16F16, showed significant anticancer activity in in vitro and in vivo ovarian cancer models (Xu et al., 2012, 2014). The terminal propynoic group of PACMA covalently reacts with the thiol groups of the active-site cysteines in PDI. This interaction also changes the secondary protein structure of PDI. RB-11-ca, arsenic-containing compounds, sulphhydryl reagents, junifiderin and its analogues, quercetin-3-rutinoside, and bacitracin have been identified as possible PDI inhibitors against cancer cells (Xu et al., 2014). Among PDI inhibitor identified against cancer cells, bacitracin inhibited in vitro promastigote growth as well as amastigote propagation inside macrophages with EC50 values of 39 μM. This compound blocked both reductase and isomerase activities of PDI in Leishmania parasite (Ben Khalaf et al., 2012).

Superoxide dismutases (SODs)

SODs are considered potential cellular antioxidants in different cells since they are metalloproteins involved in the breakdown of potentially harmful oxygen molecules, preventing tissue damage. For instance, Fe-SOD protects Leishmania against radical superoxide anions using iron as a cofactor (Oppermann and Szikora, 2006; Van Assche et al., 2011). SODs are proteins encoded by conserved genes in Leishmania parasites and due to their protective function, are considered possible therapeutic and vaccine targets against leishmaniasis (Paramchuk et al., 1997; Danesh-Bahreini et al., 2011; Sanchez-Moreno et al., 2015; Martin-Montes et al., 2017; Rashidi et al., 2020a).

Alternatively, the deregulation of the redox homeostasis is implicated in several diseases, among them malignancies. It had been shown that the activity of Zn-SOD, Mn-SOD and Cu-SOD is decreased in cancer cells. Furthermore, in most brain malignant tumours, apoptosis occurs due to the expression of SODs (Younus, 2018) and are proteins inducing the progression and metastasis of pancreatic cancer cells (Oberley and Buettner, 1979). Due to the multifunctional role of these proteins, several inhibitors have been developed (Wood et al., 2001; Dumay et al., 2006; Glasauer et al., 2014). For instance, diethylthiocarbamate (DDC) has been known as an inhibitor of Cu- and Zn-SODs. DDC has antagonistic effects on apoptosis by triggering cytochrome c release and caspase inhibition (Dumay et al., 2006). In addition, it has been indicated that SOD1 by the small molecule ATN-224 induced cell death in various non-small-cell lung cancers cells (NSCLCs). ATN-224-dependent SOD1 inhibition enhanced superoxide, which decreased the enzyme activity of the antioxidant glutathione peroxidase, causing an increase in intracellular hydrogen peroxide (H2O2) levels (Glasauer et al., 2014). 2-Methoxyoestradiol, a naturally occurring metabolic product of 17-beta-oestradiol, is able to inhibit tubulin polymerization and possesses growth inhibitory and cytotoxic activity in vitro and in vivo. 2-Methoxyoestradiol also inhibited SOD in a tetrazolium salt-based enzyme assay, proposed that oestradiol derivatives could be useful starting points for the development of non-toxic, effective enzyme inhibitors (Wood et al., 2001). In addition to application in cancer therapy, due to the expression of SODs in Leishmania parasites, the SOD inhibitory property of this compound can be evaluated against these parasites. In 2017, a series of synthesized selenium derivatives showed in vitro leishmanical activities against intracellular amastigote and promastigotes forms of Leishmania braziliensis and Leishmania infantum with significant low toxicity on the parasite-infected-macrophages. Surprisingly, the most active selenium compounds were potent inhibitors of Fe-SOD in both parasite species (Martin-Montes et al., 2017). Moreover, since tubulins are expressed in Leishmania parasites and considered appropriate drug targets, the tubulin polymerization inhibitory property of 2-methoxyoestradiol, is another factor that might underline this compound as a possible drug against leishmaniasis (Morgan et al., 2008).

Phospholipase

PLC facilitates the evasion of protozoan parasites from parasitophorous vacuoles and helps to hydrolyse miltefosine in Leishmania parasites. Such critical functions highlight the role
of PLC in the pathogenicity of Leishmania parasites (Breiser et al., 1987; Moudy et al., 2001; Dorlo et al., 2012; Rashidi et al., 2020a). Other PLs such as PLA2 play major roles in Leishmania parasites virulence and maintenance in vertebrate hosts. It has been indicated that the use of PLA2 inhibitor such as bromoanol lactone (BEL) led to the reduction of lesions size and decreased the load of parasites in skin in the L. amazonensis-infected BALB/c mice. However, due to such an inhibitor also induced hepatotoxicity in BALB/c mice (Bordon et al., 2018).

PLCs as intermediate signalling factors for epidermal growth factor and ILs conduct regulatory functions in the immunology of cancers. However, the role of these proteins in the evasion of cancer cells from the host immune system remains unknown (Ramazzotti et al., 2011). The PLC-isoenzyme profile has not been investigated in Leishmania parasites so far. Nevertheless, the different forms of PLC-isoenzymes including PLC-α, PLC-β1, PLC-ε and PLC-γ1 have been characterized in breast cancer (Cai et al., 2017). It has been shown that nuclear phosphoinositide (PI)-PLC-β1 has a role in the generation, progression and resistance to apoptosis of the cancer cells in patients with myelodysplastic syndromes (MDS) (Ramazzotti et al., 2011). Other results highlighting the up-regulation of PLC-γ1 in the oral potentially malignant lesion (OPL) were correlated with the development of oral cancer (Ma et al., 2013). It was demonstrated that PLC-γ is an important marker in the pathogenicity of cancers (Lattanzio et al., 2013). The identification of PLC-isoenzymes in Leishmania parasites and the elucidation of possible functions of each PLC-isoenzyme regarding the pathogenicity and clinical manifestations of leishmaniasis might become a new approach for the development of leishmaniasis treatment. It has been shown that inhibition of phosphatidylycholine-specific PLC using tricyclodecan-9-yl-potassium xanthate (D609) selectively targeted proliferation and survival of tumour initiating cells in SCC and ovarian cancer cells. This compound prevented cancer cells from entering the S-phase under growth-factor stimulation without cell death induction (Amtmann and Sauer, 1990; Spadaro et al., 2008; Iorio et al., 2010; Cecchetti et al., 2015). Other compounds including aurintricarboxylic acid, 3013, 3017 and U73122 have been also identified as other possible PLC modulators (Bleasdale et al., 1990; Huang et al., 2013). These compounds can also be evaluated as inhibitors against PLCs in Leishmania parasites and cancer cells.

Tyrosyl-DNA-phosphodiesterase-1 (TDP-1)

TDP-1 is a PL D able to cleave the phosphodiester bond formed between the tyrosine residue of type I TOP and the 3′ phosphate of DNA. TDP-1 is involved in repairing TOP I-DNA complexes stabilized by TOP IB poisons and performs its activity by hydrolysis of the phosphodiester bond (Banerjee et al., 2010). TDP-1 has been firstly described in Leishmania donovani. Recently, indenoi-diones, a PL D-specific derivative with dual TOP IB/TDP-1 inhibitory capability has been tested against L. infantum (Gutiérrez-Corbo et al., 2019).

It has been reported the altered expression of TDP-1 in several cancers (Liu et al., 2007; Dean et al., 2014; Meisenberg et al., 2015). Moreover, single nucleotide polymorphisms are associated with poor survival among small cell lung cancer patients (Lohavanichbutr et al., 2017). Due to its repair action mechanism, TDP-1 is related to resistance to TOP I inhibitors during cancer treatments. Therefore, its status in tumours might predict the effectiveness of the TOP I inhibitors used against cancers. TDP-1 constitutes a promising target in cancer treatment; therefore, the development of inhibitors may be useful to improve the efficacy of chemotherapy (Dean et al., 2014; Mozhaftiev et al., 2019; Khomenko et al., 2020; Mamontova et al., 2020).

HSP60

HSPs categorize as a group of proteins that are regulated by different cells in response to exposure to stressful conditions. Several members of these proteins exert chaperone functions by facilitating to refold proteins that were destructed or damaged by the cell stress or by stabilizing new proteins to provide correct folding (Dubey et al., 2015). The immunostimulatory property of HSP60 and its up-regulation in Leishmania-infected cells and drug-resistant Leishmania strains lead to consider HSP60 as a valuable biomarker in the vaccination design and the treatment of leishmaniasis (Brandau et al., 1995; Celeste et al., 2004; Requena et al., 2015; Rashidi et al., 2019). During cancer development, HSP60 is overexpressed in advanced breast and serous ovarian cancers (Desmetz et al., 2008; Hjerpe et al., 2013). The expression of this protective protein leads to the angiogenesis, metastasis and survival of the cancer cells. Mostly, HSP60 exerts its functions by attaching other proteins. For instance, HSP60 promotes neuroblastoma cells survival through clusterin protein inhibition by a linkage to this protein. In addition, HSP60 binds to the β-catinen and induces metastasis in some cancer cells (Tsaï et al., 2009; Chaiwatanasirikul and Sala, 2011). The regulation of apoptosis due to the interaction of HSP60 and cyclophilin D in mitochondrion suggests the dual function of HSP60 in cancer cells (Ghosh et al., 2010). In human hepatoma Huh-7 cells, through the interaction of HSP60 with the hepatitis C virus, core proteins induce the production of reactive oxygen species (ROS) and increase the apoptosis which is mediated by TNF-α (Sherman and Multhoff, 2007; Kang et al., 2009). Based on the importance of this chaperone in the viability of both Leishmania and cancer cells, and on the existence of inhibitors targeting them (Cappello et al., 2014; Stevens et al., 2019), HSP60 might be consider a promising therapeutic target against these pathologies. Three known antibiotics (suramin, rafoxanide and closantel) and epolactae and myrtucommulone have been identified as inhibitors of human HSP60 chaperonin (Meng et al., 2018; Stevens et al., 2019). The use of suramin, as first-line chemotherapeutic agent, against Trypanosoma brucei rhodesiense and T. brucei gambiense, might suggest the evaluation of this HSP60 inhibitor against leishmanial-HSP60 (Abdeen et al., 2016; Zininga and Shonhai, 2019). Although the exact mechanism action of this compound remains unknown, probably inhibits some glycolytic enzymes (Willson et al., 1993; Zininga and Shonhai, 2019). Sinularin, a compound extracted from the coral Sinularia flexibilis, is able to inhibit HSP60 in melanoma cell-A2058 (Su et al., 2012). It has been also shown that bortezomib, a proteasome inhibitor, exhibited its anti-tumour efficacy by increasing HSP60 and HSP90 expression on the surface of cancer cells and inducing phagocytosis in experimental model of ovarian cancer (Chang et al., 2012).

HSP90

HSP90 is a molecular chaperone important to the stability, folding and activity of over 200 proteins responsible for tumour initiation, development and metastasis. This protein is important for survival and proliferation of protozoan parasites during their intra-cellular mammalian stage. Since the ATPase activity executed in the N-terminal domain of HSP90 is critical for chaperone functions, HSP90 inhibitors capable to prevent ATP hydrolysis are expected to inhibit HSP90, leading to protein degradation and cell death, making this chaperone an attractive putative therapeutic target for cancer and leishmaniasis treatment (R Woodford et al., 2016; Palma et al., 2019; Batista et al., 2020). 17-N-Allylamino-17-demethoxygeldanamycin (17-AAG, tanezumimycin) is an inhibitor of HSP90, which has been investigated
in the treatment of cancer such as solid tumours and leukaemia. Alternatively, geldanamycin, and its analogues, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) and 17-AAG, may show a promising therapeutic activities against leishmaniasis (binding to the N-terminal domain of leishmanial-HSP90). However, the delivery of 17-AAG is difficult because of its poor aqueous solubility (Palma et al., 2019; Pires et al., 2020). Moreover, several molecules including Glb02, Glb08, Glb11, Glb16, Glb25 and Glb27 have been suggested as leishmanial-HSP90 inhibitors via binding to the N-terminal region of this protein (Batista et al., 2020).

**Aldehyde dehydrogenase (ALDH)**

ALDHs are a group of enzymes found in all subcellular compartments that transform aldehydes to carboxylic acids. In Leishmania, ALDH is located in the mitochondrion (mALDH) and is overexpressed in the promastigote forms compared to the amastigotes (Saxena et al., 2007). It has been suggested as a protective protein against oxidative stress during glucose limitation in these parasites (Feng et al., 2011). Its expression significantly decreases in long culture of Leishmania and mALDH might be related to virulence (Magalhaes et al., 2014). Although different ALDH-isoenzymes have been identified in NSCLCs, the expression of such isoenzymes is unknown in Leishmania (Kang et al., 2016). The low expression of ALDH in normal IMR-90 human lung cells and in Leishmania spp. with attenuated infectivity may highlight the major role of ALDH in the pathogenicity of cancer and leishmaniasis (Bringaud et al., 1995; Chavali et al., 2008; Brocker et al., 2010; Feng et al., 2011; Kang et al., 2016). The high level of ALDH has been reported in drug-resistant cancer stem cells (Januchowski et al., 2013; Clark and Palle, 2016; Vassalli, 2019). It has also been shown that the use of N,N-diethylaminobenzaldehyde (DEAB) and a combination of gossypol (a pan-ALDH inhibitor) and phenformin leads to cancer cell death (Kang et al., 2016; Jiménez et al., 2019). The antiparasitic efficacy of gossypol, as an ALDH inhibitor, has been previously highlighted (Koppaka et al., 2012). A recent study has identified potential anticancer agents, as potent multi-ALDH isoform inhibitors, increased lipid peroxidation, ROS activity and toxic aldehyde accumulation, and also causing increased apoptosis and G2/M phase cell cycle arrest (Dinavahi et al., 2020). Such inferred data from cancer cells might clarify the possible function of ALDH in drug-resistant Leishmania strains and suggest the use of ALDH-isoform inhibitors not only for cancer treatment (Dinavahi et al., 2020), but also as a promising strategy for therapeutic assessments against leishmaniasis.

**Topoisomerases (TOPs)**

TOPs are a group of enzymes that catalyse changes in the DNA topology during replication, transcription, recombination and genome repair. Firstly, they repeatedly can cut and join phosphodiester bonds from the phosphate deoxyribose structure which harbouring nitrogenous bases encoding genetic message. Secondly, they allow other DNA chains to pass between the temporary formed tails, by using energy from the nucleotide linkage and bind covalently to 3' or 5'-DNA end (Wang, 2002; Pommier et al., 2016).

**TOP IB**: Type IB TOPs cut one DNA strand and covalently join to 3' end. Two types of TOP IB inhibitors have been described: type I inhibitors or poisons, which stabilize the cleavage complex by creating a ternary complex DNA–enzyme drug; and type II inhibitors which act on the catalytic function of the enzyme. Despite their relevant role in genetic information fidelity conservation, TOP IB from Leishmania parasites are heterodimer enzymes which deeply differ from those of humans. For this reason, Leishmania TOP IB are considered as potential therapeutic targets. Camptothecins and their derivatives have demonstrated inhibitory activities against these parasitic enzymes (Prada et al., 2013). Synthetic indenoisoquinolines are potent TOP IB inhibitors with leishmanicidal activity ‘in vivo’ (Balaña-Fouce et al., 2012). Recently, hybrids of isoquinolines and camptothecins have shown their leishmanicidal activity through TOP IB activity inhibition (Reguera et al., 2019). Similarly, natural alkaloids and marine fatty acids have been reported as Leishmania TOP IB inhibitors (Carballeira et al., 2009, 2011, 2012a, 2012b, 2013; Chowdhury et al., 2011; Kumar et al., 2015, 2016; Pérez-Perejo et al., 2019) as well as anticancer compounds (Carballeira et al., 2016, 2018).

On the other hand, human TOP I is a monomeric enzyme which has been demonstrated being overexpressed in several cancers (Lynch et al., 2001; Berney et al., 2002; Gouveris et al., 2007; Kübler et al., 2015). Most of the marketed TOP inhibitors applied for cancer treatment target TOP type II. However, there are camptothecin derivatives approved such as irinotecan, topotecan and belotecan (Hevener et al., 2018) which use TOP IB as a target.

**TOP II**: Type II TOPs are homodimeric enzymes responsible for catalysing topological changes in the DNA by transitory break of both nucleotide chains. During this process an intermediate covalent, between 5'-ends and such enzymatic subunits, is formed. Those proteins are conserved in blood parasites such as Plasmodium, Trypanosoma or Leishmania and their mammal hosts. However, the emerging interest on Leishmania TOP II was mainly due to its involvement in the kinetoplast DNA network and its replication. Moreover, TOP II is related to drug resistance in these parasites (Jayanarayan and Dey, 2003; Sengupta et al., 2005; Singh et al., 2009). The overexpression of a TOP II-like enzyme activity has highlighted the regulatory functionality of this putative enzyme in arsenite-resistant L. donovani strains (Jayanarayan and Dey, 2003). A point mutation, R250G, has been detected in the ATPase domain of the TOP II in arsenic-resistant strain of L. donovani parasite. The variation in the TOP II gene sequence between arsenite-sensitive and -resistant strains is anticipated to be responsible for the varied behaviour of this enzymes in response to antileishmanial anti-TOP II agents (Singh et al., 2009). As aforementioned, similarly to TOP IB targeting agents, there are two groups of TOP II inhibitors depending of their mode of action, and some of them are even able to target both, type I and type II TOPs (Ray et al., 1997). For instance, isobenzofurane derivatives are capable to inhibit Leishmania TOP II linked to DNA (Mishra et al., 2014; Chowdhury et al., 2018), whereas protoberbine perform its effect by stabilizing TOP II–DNA cleavage complex (Marquis et al., 2003). Mitonafide had demonstrated its activity on Leishmania nuclear and kinetoplast-TOP II (Slunt et al., 1996). Recently, a mitonafide derivative has shown a Leishmania TOP II inhibitory effect similar to type I inhibitors and at the mRNA level (Fernández-Rubio et al., 2019).

Human TOP II presents two isoforms: alpha (TOP 2A) and beta (TOP 2B) which exhibit differences in their molecular weight, genetic regulation and the location of the active site. TOP II expression in cancer lines has been largely studied (Doyle, 1994). Although TOP 2B isoform is expressed relatively constant throughout the cell cycle in both, normal and transformed cells, TOP 2A has been found abnormally expressed in different cancers such as breast, lung or prostate among others (Giaccone et al., 1995; Depowski et al., 2000; Mrklic et al., 2014; Schaef er-Klein et al., 2015; An et al., 2018; Liu et al., 2018). In fact, there are marketed anticancer drugs targeting TOP II, such as anthracycline and podophyllotoxin derivatives (Hevener et al., 2018). Etoposide, which belongs to the last
group, is the best known TOP II poison, stabilizing DNA cleavage complex. Currently, TOP II molecules continue being a promising therapeutic target against cancer, and numerous research projects have focused on the synthesis of new inhibitors (Liberio et al., 2015; Karelia et al., 2017; Jiang et al., 2018; Yamashita et al., 2018; Li et al., 2018b).

**Proliferating cell nuclear antigen**

PCNA is a processivity factor for DNA polymerase delta (Pol δ) and epsilon (Pol ε). It also interacts with other proteins involved in cell-cycle progression which are not parts of the DNA polymerase complex. PCNA has demonstrated its role in the replication and repair of DNA, chromatin assembly and RNA transcription. Its importance in *Leishmania* pathology is related to its significant role in drug response in clinical isolates (Tandon et al., 2014). In addition, this protein is a potential therapeutic target against leishmaniasis since it showed susceptibility to be inhibited at the mRNA level by selenocompounds (Fernández-Rubio et al., 2015; Fernández-Rubio et al., 2019). It is known that PCNA is overexpressed in tumour cells, to adapt the high capacity of such cells to exhibit an uncontrolled replication (Naryzhny and Lee, 2007). Interestingly, there are several small molecules, including cell-penetrating peptides, targeting PCNA with promising results against breast cancer and other tumours. For instance, several compounds inhibit the association of PCNA and chromatin, resulting in apoptosis and DNA damage in prostate and lung cancer (Dillehay et al., 2014; Lu and Dong, 2019). A cell penetrating peptide had been described as caspase-dependent apoptosis inducer which increased the activity of antitumour treatments in multiple myeloma cells (Muller et al., 2013).

**Tubulins**

Tubulins are highly conserved dimeric proteins present in all eukaryotes. Alpha-beta (αβ) dimers polymerize to form microtubules, which serve as a skeletal system for living cells and participate in several essential functions, such as mitosis or intracellular transport among others (Montecinos-Franjola et al., 2019). In *Leishmania*, α-tubulin is a key component of the cytoskeleton, responsible for cell shape and involved in cell division, ciliary and flagellar motility (Ramirez et al., 2013). In addition, it has been related to drug resistance (Prasad et al., 2000; Jayaranayan and Dey, 2004). Furthermore, proteomic analyses demonstrated that this protein is more abundant in *Sb(III)-resistant Leishmania* cell lines (Matrangolo et al., 2013). Due to its role in *Leishmania* biology and pathology, α-tubulin has been considered a promising target against leishmaniasis and, consequently, compounds targeting this protein have been tested. Selenocompounds were able to significantly reduced α-tubulin gene expression (Fernández-Rubio et al., 2015). Podophyllin derived toxins are *Leishmania* tubulin inhibitors however, those showed discrepancies between protein activity and parasite growth inhibition (Escudero-Martínez et al., 2017). Such results differ from those of colchicine against trypanosomatids. This potent inhibitor of tubulin polymerization in higher eukaryotes seems to lack activity against these parasites, probably due to conformational changes in the protein which block colchicine access (Luis et al., 2013).

Alterations in the expression of tubulin are related to drug resistance in different cancers, including breast, lung, ovarian, gastric and prostate (Bernard-Martuy et al., 2002; Hwang et al., 2013; Jiang et al., 2013; Tsourlakis et al., 2014; Du et al., 2015). Depending of their mechanism of action, tubulin inhibitors could be mainly grouped as microtubule-destabilizing agents or microtubule-stabilizing agents (Perez, 2009). The firsts are colchicine analogues and vinca alkaloids. The seconds are paclitaxel derivatives. Colchicine analogues bind to the colchicine binding site (CBS), one of the most important pockets for potential tubulin polymerization destabilizers. These compounds inhibit tubulin assembly and suppress microtubule formation (Lu et al., 2012). Nevertheless, currently there are not FDA (Food and Drug Administration) approved tubulin inhibitors targeting the CBS (Li et al., 2018a, 2018b). Taxanes, such as paclitaxel and its derivatives, bind to the interior surface of microtubules, resulting in their stabilization. Therefore, microtubules stabilization increase, leading to cell cycle arrest and apoptosis (Jordan, 2002; Jordan and Wilson, 2004).

**Voltage-dependent anion-selective channel protein 1 (VDAC-1)**

VDAC-1 forms a large channel in the outer mitochondrial membrane that allows the diffusion of hydrophilic molecules. Apoptosis, metabolic flux and intracellular signalling are also important functions of this porin in eukaryotes. *Leishmania* parasites use anionic voltage-dependent channels as a transport system for adaption to nutritional stress conditions and pH homoeostasis (Vieira et al., 1994; Lawen et al., 2005; Shoshan-Barmatz et al., 2006; Bayhuber et al., 2008).

In cancer cells, VDAC-1 is a protein with dual function involved in the regulation of survival and mitochondria-mediated apoptosis (Shoshan-Barmatz et al., 2017). It has been shown that the use of VDAC-1-specific small interfering RNA leads to the metabolism alteration and the growth suppression of cancer cells. Moreover, the up-regulation of the VDAC-1 increases the expression of apoptotic proteins such as hexokinase (HK), B-cell lymphoma-xL (Bcl-xL) and Bcl-2 in cancer cells and leads to the growth inhibition of such cells. Ion channel blockers have demonstrated activity against ion channel proteins in both, cancer cells and *Leishmania* parasites (Ponte-Sucre et al., 1998; Kale et al., 2015; Leanza et al., 2016; Reimão et al., 2016; Shoshan-Barmatz et al., 2017). Verapamil and nifedipine have been identified as human calcium channel blockers in cancer therapy which had been proposed to have mild anti-leishmanial activity (Kashif et al., 2017). *Leishmania donovani* Ca\(^+\) ion channel (Ld-CC) has been suggested as potential drug target in leishmaniasis treatment (Kashif et al., 2017). Ld-CC regulates Ca\(^++\) concentration which is involved in several functions such as mitochondrial oxidative metabolism and entry inside the macrophages and flagellar motion. Two ligands, ZINC17287336 and ZINC29590262 were shown highest binding affinity towards Ld-CC. These selected compounds have relatively more binding affinity than verapamil and nifedipine. Since ZINC29590262 has shown poor binding affinity towards the human voltage-dependent L-type calcium channel subunit alpha-1C in comparison with the Ld-CC, this compound can be suggested as an appropriate drug target (40% more binding affinity with Ld-CC than the human-voltage-dependent calcium channel) (Kashif et al., 2017).

**Mitochondrial import receptor subunit (TOM-40)**

TOM-40 is located at the core of the translocate of the outer membrane (TOM) structure. Data produced by genome sequencing in protozoa has indicated the presence of TOM-40 homologues in *Cryptosporidium* (Keithly et al., 2005; Umejego et al., 2008). Recent studies have reported TOM-40 in *L. infantum* amastigotes, and a protein with low similarity to TOM-40 in *Trypanosoma* (Zarsky et al., 2012; Rashidi et al., 2019). Although, the function of TOM-40 in *Leishmania* is unknown, bioinformatics data of the *T. brucei* genome for both TOM-40 and VDAC have identified a single open reading frame, with sequence analysis suggesting that TOM-40s and VDACs are...
ancestrally related and should be classified into the same protein family (the mitochondrial porins) (Pusnik et al., 2009). This information might open an attractive insight about using ion channel blockers against both TOM-40s and VDACs in Kinetoplastida such as *Trypanosoma* and *Leishmania* parasites.

As a tumour marker, TOM-40 is up-regulated in ovarian cancer cells and induces the proliferation and metastasis of these cells *‘in vitro’*. It seems that TOM-40 increases the replication of cancer cells through regulating the mitochondrial activity and improving cellular energy and redox status (Yang et al., 2020). Evidence has shown that the inhibition of TOM-40 expression in ovarian cancer cells leads to a reduction in the proliferation and migration of cancer cells. However, directly targeting TOM-40 may be challenging in clinical application due to its substantial expression in normal cells. Since metformin (first-line therapy for type 2 diabetes) has been already clinically used with lower side-effects, this compound can be an appropriate alternative drug for targeting TOM-40 and the mitochondria (inhibiting mitochondria complex I) in epithelial ovarian cancer (Yang et al., 2020). The pathogenic functions of TOM-40 and therapeutic strategy against this target in cancer treatment might persuade the scientists to further investigate the expression and possible functions of TOM-40 in pathogenesis of leishmaniasis.

**Ornithine aminotransferase (OAT)**

Aminotransferase are important enzymes that are able to transaminase aromatic amino acids. The functions of OAT are related to L-arginine pathways involved in polyamines production (Muxel et al., 2018). Polyamines metabolism is strongly important for *Leishmania* cell proliferation and infection (Ilari et al., 2015). For instance, a recent study has evaluated the effect of polyamine depletion in *L. donovani* mutants lacking ornithine decarboxylase or spermidine synthase. As mentioned in Table 1, DFM0 inhibitor of ornithine decarboxylase, the enzyme that catalyses putrescine biosynthesis. Those results suggested that putrescine is not only a precursor metabolite for spermidine formation; it had specific functions for parasite viability and proliferation. These results also elucidated that ornithine decarboxylase inhibition and putrescine depletion was the most promising strategy for targeting polyamine biosynthetic pathway. It seemed that both polyamines (ornithine decarboxylase or spermidine) were required for parasite survival but that the presence of either putrescine or spermidine alone may allow *Leishmania* parasites to survive in a quiescent-like state for several weeks (Perdeh et al., 2020).

OAT as a β-catenin target gene in the liver is involved in the metabolism of glutamine. It has been shown that in hepatocellular carcinoma (HCC), the expression of OAT is up-regulated and the mechanism of this gene up-regulation is related to the activation of β-catenin signalling (Cadoret et al., 2002; Colnot et al., 2004). This information proposed that OAT, β-catenin signalling and the metabolism of glutamine are important factors in carcinogenesis especially in HCC (Cadoret et al., 2002; Thompson and Monga, 2007). The existence of inhibitors targeting OAT used to block the proliferation of HCC, may also allow the selection of this transference as a therapeutic target against *Leishmania* parasites (Zigmond et al., 2015).

**Selenoproteins and selenoamino acid**

Selenoproteins are a group of enzymes bearing selenocysteine in their catalytic domain. Many of the Se-bearing proteins participate in oxidative stress protection as observed in *Leishmania* parasites (Iribar et al., 2003; Da Silva et al., 2014). The use of leishmanial selenoproteins and selenoamino acid (selenomethionine) as therapeutic targets due to their role in modulation and evasion of the host immune responses has been recently suggested (Rashidi et al., 2020a, 2020b).

The role of selenoproteins and their metabolites including methylselenol, selenodiglutathione, Se-methylselenocysteine and selenomethionine has been underlined in the metabolism of lung cancer cells (Seng and Tieikink, 2012). Such metabolites inhibit protein kinases and alter cell cycle in cancer cells. Furthermore, these metabolites induce the activity of lymphokine-activated killer cells and natural killer cells and finally stimulate the immune system against cancer cells (Seng and Tieikink, 2012). The use of leishmanial selenoproteins inhibitors as well as the anti-tumour property of selenoproteins and their metabolites against cancer cells might suggest that such aforementioned compounds represent therapeutic targets for the treatment of leishmaniasis and cancers. Auranofin is a gold-containing compound with well-known selenoproteins synthesis inhibitor properties. Its activity has been demonstrated against thioredoxin reductase (TrxRd), a Se-bearing enzyme involved in maintaining the intracellular redox state. In cancer, TrxRd overexpression is related to the aggressiveness of the malignancy (Kahlos et al., 2003; Lincoln et al., 2003) and its inhibition lead to apoptosis of tumour cells (You and Park, 2016). Using drug repurposing strategy, auranofin had been tested against parasitic diseases including *Leishmania*, with promising results. However, this compound seems not to target selenoproteins in these parasites, but rather interact with trypanothione reductase, a key enzyme of *Leishmania* polyamine-dependent redox metabolism (Ilari et al., 2012; Sharlow et al., 2014; Manhas et al., 2016). Nevertheless, the existence of specific selenoproteins inhibitors with effective activities against cancer cells might support the role of leishmanial selenoproteins as therapeutic targets (Yan et al., 2015; Arné, 2017).

**Phosphoglycerate kinase-1 [PKG-1 (PKG-B)]**

PGKs are transferases involved in ATP production from ADP and 1,3-diphosphoglycerate. Their involvement in the glycolytic pathway and survival of *Leishmania* parasites has been previously reported (Hart and Opperoeds, 1984; Blattner et al., 1992; Azvedo et al., 2015). PGKs (PKG-B) are overexpressed in antimony-resistant strains of *Leishmania*. Therefore, they might be related to the pathogenicity of these parasites (Blattner et al., 1998; Kazemi-Rad et al., 2013). Increased level of glycolysis enzymes such as PGK in the antimony resistant *Leishmania* isolates suggesting resistant strains require higher energy to protect against antimony-induced oxidative stress. Alternatively, the over-expression of such enzyme might lead to enhancing in pyruvate which can remove peroxides and participate to reduce oxidative stress (Biyani et al., 2011). In both, *Leishmania* and mammalian cells, PGKs are encoded by two genes: *gene B* and *gene C*, and PGK-1 and PGK-2, respectively (Watson and Littlechild, 1990; McKay et al., 1997). Several monosubstituted N6 and N2 adenine derivatives were selected to screen against *T. brucei* PGK. Of these, 2-amino-N6-substituted analogues represented appropriate activity against the parasite kinase compared with the N6 compounds that lacked the C2 amino group, although activity was still weak (Merritt et al., 2014). Since protein kinase inhibition has been primarily discussed as anti-trypanosomatid strategy in treatment, these proteins such as PGK can further investigated in leishmaniasis.

The importance of PGK-1 in cancer development resides on its involvement in drug-resistance and its dual action depending on the cellular environment. Under intracellular hypoxia conditions, it plays an oncogenic role. However, it decreases tumour growth when it is secreted extracellularly through angiogenesis inhibition (Daly et al., 2004; He et al., 2019). In addition to the metabolic functions of PGK-1 in cancer cells, this enzyme induces
and increases the angiostatin formation and leads to the restriction of angiogenesis in tumours. The anti-tumour property of PGK-1 has been shown in Lewis lung carcinoma (LLC-1). It is well known that cyclooxygenase-2 (COX-2), as an important marker of resistance to apoptosis in cancer cells, promotes angiogenesis and metastasis (Tsujii and DuBois, 1995; Tsujii et al., 1998). Due to the overexpression of PGK-1 in LLC-1, COX-2 is decreased and therefore, cell invasion, prostaglandin E2 and angiogenesis are affected by this mechanism. Finally, the progression of cancer cells is then restricted (Tang et al., 2008; Ho et al., 2010). Under solid tumours and hypoxia conditions, PGK-1 is the main source of production of ATP. Solid tumour cells use mechanisms that inhibit the production of PGK and decrease the angiostatin formation. Furthermore, other angiogenesis activators such as vascular endothelial cell growth factor are active in solid tumours (Daly et al., 2004). Currently, potential PGKs-inhibitors are under development (He et al., 2019).

Conclusion

The up-and-down-regulation of the aforementioned proteins were mostly related to the survival, development, pathogenicity, metabolic pathways and vital signalling in Leishmania parasites and cancer cells. As an interesting issue, the regulation of these markers can be investigated in interactions that can be occurred between Leishmania parasites and cancer cells under ‘in vivo’ and ‘in vitro’ conditions. The reliable validation of the expression of such proteins in Leishmania parasites and cancer cells using further experiments is warranted to subsequently confirm their possible functions. Further investigation of the differentially regulation of common expressed proteins between cancer cells, normal human cells, low-pathogenic and high-pathogenic forms of Leishmania parasites might elucidate novel and attractive information concerning such proteins. The existence of common triggering factors reflects mutual features in the etiopathogenetic mechanisms underlying leishmaniasis and cancer. Given these similarities, lessons learned from strategies against cancer may be relevant to design adequate approaches to reduce and eliminate leishmaniasis. Herein, we focused specifically on the shared mechanisms at protein scale. Taken together, the introduction of common expressed proteins in Leishmania parasites and cancer cells might reveal valuable information regarding the possible common mechanisms of pathogenicity and therapeutic targets in leishmaniasis and cancers. Taking into account that current therapies for neglected diseases are based in drugs lacking effectiveness, the lack of new specific anti-Leishmania compounds and of research focused on this group of diseases, drug repurposing constitutes a useful tool to find effective candidates in leishmaniasis control and elimination. This review reinforces the likely functional similarities between many proteins in cancer and parasites, some of them being recognized therapeutic targets and thus the potential use of drugs with proven efficacy in the treatment of cancer for treating parasitic diseases and vice versa, opening new avenues to the one health approach.

Acknowledgements. PN gratefully acknowledges support provided by Fundación La Caixa (LCF/P2/PR13/11080005) and Fundación Caja Navarra, Gobierno Navarra Salud (12/2017), Fundación Roviralta, Ubesol, Government of Navarre, Laser Ebro and Inversores Garciaso de la Vega S.L.

Financial support. This study was supported by the National Institute for Medical Research Development (NIMAD), Tehran, Iran, grant number 971405.

Conflict of interest. The authors declare there are no conflicts of interest.

Ethical standards. Not applicable.

References

Abdeen S, Salim N, Mammadova N, Summers CM, Goldsmith-Pestana K, Mathewson-Pratt D, Schultz AL, Horwich AL, Chapman E and Johnson SM (2016) Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness. Bioorganic & Medicinal Chemistry 26, 5247–5253.

Achour YB, Chenik M, Louizir H and Delliagi K (2002) Identification of a disulfide isomerase protein of Leishmania major as a putative virulence factor. Infection and Immunity 70, 3576–3585.

Afrin F, Khan I and Hemeg HA (2019) Leishmania-host interactions-an epi-genetic paradigm. Frontiers in Immunology 10, 492.

Al-Kamel MAN (2017) Leishmaniasis and malignancy: a review and perspective. Clinical Skin Cancer 2, 54–58.

Amit A, Dikhit MR, Singh AK, Kumar V, Suman SS, Singh A, Kumar A, Thakur AK, Das VR and Das P (2017) Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. Molecular Immunology 82, 104–113.

Ammann E and Sauer G (1990) Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogene and lauric acid. International Journal of Cancer 45, 1113–1118.

An X, Xu F, Luo R, Zheng Q, Lu J, Yang Y, Qin T, Yuan Z, Shi Y and Jiang W (2018) The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer 18, 1–10.

Antony S, Kohlhagen G, Agama K, Jaryaman M, Cao S, Durran FA, Rustum YM, Cushman M and Pommier Y (2005) Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison. Molecular Pharmacology 67, 523–530.

Arab S, Motamedi M and Hadijia J (2019) Effects of dendritic cell vaccine activated with components of Leishmania major on tumor specific response. Iranian Journal of Immunology 16, 268–277.

Arnér ES (2017) Targeting the selenoprotein thioredoxin reductase 1 for anticancer therapy. Advances in Cancer Research 136, 139–151.

Azevedo A, Toledo JS, Delfina T, Pedroza AL and Cruz AK (2015) Leishmania major phosphoglycerate kinase transcript and protein stability contributes to differences in isoform expression levels. Experimental Parasitology 159, 222–226.

Balala-Fouce R, Prada CF, Requena JM, Cushman M, Pommier Y, Álvarez-Velilla R, Escudero-Martínez JM, Calvo-Álvarez E, Pérez-Pertejo Y and Requera RM (2012) Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis. Antimicrobial Agents and Chemotherapy 56, 5264–5270.

Banerjee B, Roy A, Sen N and Majumder HK (2010) A tyrosyl DNA phosphodiesterase 1 from kinetoplastid parasite Leishmania donovani (LdTdp1) capable of removing topo 1-DNA covalent complexes. Molecular Microbiology 78, 119–137.

Batista FA, Ramos SL, Tassone G, Leitão A, Montanari CA, Botta M, Mori M and Borges JC (2020) Discovery of small molecule inhibitors of Leishmania braziliensis HSP90 chaperone. Journal of Enzyme Inhibition and Medicinal Chemistry 35, 639–649.

Bayrhuber M, Meins T, Habeck M, Becker S, Giller K, Villinger S, Vonrenhin C, Griesinger C, Zweckstetter M and Zeth K (2008) Structure of the human voltage-dependent anion channel. Proceedings of the National Academy of Sciences 105, 15370–15375.

Ben Khalaf N, Muylder G, Louizir H, McKerrow J and Chenchik M (2012) Leishmania major protein disulfide isomerase as a drug target. Parasitology Research 110, 1911–1917.

Bernard-Martí C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Ganceberg D, Bissexy MG, Paesmans M, Larimont D and Piccart MJ (2002) Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical Breast Cancer 3, 341–345.

Berney D, Shamash J, Gaffney J, Jordan S and Oliver R (2002) DNA topoisomerase I and II expression in drug resistant germ cell tumours. British Journal of Cancer 87, 624–629.

Biyani N, Singh AK, Mandal S, Chowla B and Madhubala R (2011) Differential expression of proteins in antimony-susceptible and resistant isolates of Leishmania donovani. Molecular and Biochemical Parasitology 179, 91–99.
Carballeira NM, Montano N, Alvarez-Velilla R, Prada CF, Reguera RM and Balaña-Fouce R (2013) Synthesis of marine α-methoxylated fatty acid analogs that effectively inhibit the topoisomerase IB from *Leishmania donovani* with a mechanism different from that of camptothecin. *Marine Drugs* 11, 3661–3675.

Carballeira NM, Montano N, Amador LA, Rodrigues AD, Golosko MY, Golosko SA, Reguera RM, Alvarez-Velilla R and Balaña-Fouce R (2016) Novel very long-chain α-methoxylated A5, 9 fatty acids from the sponge *Asteropsis niger* are effective inhibitors of topoisomerase IB. *Lipids* 51, 245–256.

Carballeira NM, Morales-Guzman C, Alvarez-Benedicto E, Torres-Martinez Z, Delgado Y, Griebenow KH, Tinoco AD, Reguera RM, Perez-Peijto Y and Carbayo-Andres R (2018) First total synthesis of α-phenyl Δ6 fatty acids and their leishmanial and anticancer properties. *Current Topics in Medicinal Chemistry* 18, 418–427.

Carrillo-Larco RM, Acevedo-Rodriguez JG, Altez-Fernandez C, Ortiz-A K and Ugarte-Gil C (2019) Is there an association between cutaneous leishmaniasis and skin cancer? A systematic review. *Wellcome Open Research* 4, 110.

Cecchetti S, Bortolomai I, Ferri R, Mercurio L, Canevari S, Podo F, Miotti S and Iorio E (2015) Inhibition of phosphatidylinositol-specific phospholipase C interferes with proliferation and survival of tumor initiating cells in squamous cell carcinoma. *PLoS One* 10, e0136120.

Celeste B, Angel SO, Castro L, Gildlund M and Goto H (2004) *Leishmania infantum* heat shock protein 83 for the serodiagnosis of tegumentary leishmaniasis. *Brazilian Journal of Medical and Biological Research* 37, 1593–1599.

Cencini E, Lazzi S and Fabbri A (2015) Atypical clinical presentation of visceral leishmaniasis in a patient with non-Hodgkin lymphoma. *European Journal of Haematology* 2, 186–186.

Chalwataasinirulk and Kasa A (2011) The tumour-suppressive function of CuII is explained by its localisation and interaction with HSP 60. *Cell Death & Disease* 2, e219–e219.

Chakraborty S, Srivastava A, Jha MK, Nair A, Pandey SP, Srivastava N, Kumar S, Singh S, Krishnaswathy MW and Saha B (2015) Inhibition of CD40-induced N-Ras activation reduces *Leishmania major* infection. *The Journal of Immunology* 194, 3852–3860.

Chang CL, Hsu YT, Wu CC, Yang YC, Wang C, Wu TC and Hung CF (2012) Immune mechanism of the antitumor effects generated by bortezomib. *The Journal of Immunology* 189, 3209–3220.

Chavali AK, Whittemore JD, Eddy JA, Williams KT and Papin JA (2008) Systems analysis of metabolism in the pathogenic trypanosomatid *Leishmania major*. *Molecular Systems Biology* 4, 177.

Cheeseman K and Weitzman J (2017) Comment et pourquoi un parasite peut-il être ‘transformant’? Apports d’agents de zoonoses exotiques, *Theoréia* spp., à l’étude du cancer. *Bulletin de la Société de Pathologie Exotique* 110, 55–60.

Chen Y and Zhou X (2020) Research progress of mTOR inhibitors. *European Journal of Medicinal Chemistry* 208, 112820.

Chowdhury S, Mukherjee T, Sengupta S, Chowdhury SR, Mukhopadhyay S and Majumder HK (2011) Novel betulin derivate compounds as antileishmanial agents with mode of action targeting type IB DNA topoisomerase. *Molecular Pharmacology* 80, 694–703.

Chowdhury SR, Godinho JLP, Vinayagam J, Zuma AA, Silva STDM, Jaisankar P, Rodrigues JCF, De Souza W and Majumder HK (2018) Isbenzonefurane derivative JYPH3, an inhibitor of *L. donovani* topoisomerase II, disrupts mitochondrial architecture in trypanosomatid parasites. *Scientific Reports* 8, 1–11.

Clark DW and Palle K (2016) Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. *Annals of Translational Medicine* 4, 518.

Claudio U, Alessandro O, Luca C, Jacopo V and Katia F (2019) Visceral leishmaniasis in a patient with lung tumour: a case report. *Tropical Doctor* 49, 147–149.

Colnot S, Decaens T, Niws-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M and Perret C (2004) Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas. *Proceedings of the National Academy of Sciences* 101, 17216–17221.

Costa CA, Lopes RM, Ferraz LS, Esteves GN, Di Iorio JF, Souza AA, de Oliveira IM, Manarin F, Judice WA and Stefani HA (2020) Cytotoxicity of 4-substituted quinoline derivatives: anticancer and antileishmanial potential. *Bioorganic & Medicinal Chemistry* 28, 115511.
Espinosa AV, Costa D, Tunees LG, Monte-Neto R, Grazul RM, de Almeida
Cowell AN and Winzeler EA (2019) Advances in omics-based methods
to identify novel targets for malaria and other parasitic protozoan infections. Genome Medicine 11, 654–663.
Dacher M, Tchawiwa H, Horikoshi N, Kujirai T, Taguchi H, Kimura M and Kurumizaka H (2019) Incorporation and influence of Leishmania histone H3 in chromatin. Nucleic Acids Research 47, 11637–11648.
Daly ER, Wind X-M, Sun L and Hogg PJ (2004) Secretion of phos-
phoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1691, 17–22.
Da Silva M, Silva-Jardim I and Thiennont O (2014) Biological implications of selenium and its role in trypanosomiasis treatment. Current Medicinal Chemistry 21, 1772–1780.
Dean RA, Fam HK, An J, Choi K, Shimizu Y, Jones SJ, Boerkoel CF, Interthal H and Pfeifer TA (2014) Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays. Journal of Biomolecular Screening 19, 1372–1382.
De Martel C, Forfey J, Franceschi S, Vignat J, Bray F, Forman D and Plummer M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology 13, 607–615.
Den Boer M, Argaw D, Jannin J and Alvar J (2014) Secretion of phosphoglycerate kinase from tumour cells is controlled by oxygen-sensing hydroxylases. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1824, 137–146.
Diop S, Rosenthal SI, Brien TP, Stylos S, Johnson RL and Ross JS (2000) Topoisomerase IIA expression in breast cancer: correlation with outcome variables. Modern Pathology 13, 542–547.
Dos Santos Nogueira F, Avino VC, Galvis-Ovallos F, Pereira-Chioccola VL, Dorlo TP, Eggelte TA, de Vries PJ and Beijnen JH (2014) Topoisomerase IIA inhibition of podophyllotoxin derivatives on Leishmania infantum promastigotes. Antimicrobial Agents and Chemotherapy 60, 633–642.
Ferreiro S, Palmieri C, Cavicchioli L, Zan GD, Aresa L and Benali S (2013) Leishmania amastigotes in neoplastic cells of 3 nonhistiocytic canine tumors. Veterinary Pathology 50, 749–752.
Fuentes MA, Alonso C and Pérez JM (2003) Biochemical modulation of cis-
platin mechanisms of action: enhancement of antitumor activity and cir-
cumvention of drug resistance. Chemical Reviews 103, 645–662.
Ghosh JC, Siegelin MD, Dohi T and Altieri DC (2010) Heat shock protein 60 inactivation of the mitochondrial permeability transition pore in tumor cells. Cancer Research 70, 8986–8993.
Giaccone G, van Ark-Otte J, Scagliotti G, Capranico G, van der Valk P, Rubio G, Dalesio O, Lopez R, Zunino F and Balwobber J (1995) Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochimica et Biophysica Acta (BBA)-Gene Structure and Expression 1264, 337–346.
Glaxauser A, Sena LA, Diebold LP, Mazar AP and Chandel NS (2014) Targeting SOD1 reduces experimental non-small-cell lung cancer. The Journal of Clinical Investigation 124, 117–128.
Gouveris P, Lazaris A, Papathomas T, Nonni A, Kyriakou V, Delladetsima J, Patsouris E and Tsavaris N (2007) Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology 133, 1011–1015.
Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK and Dube A (2007) Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes. Proteomics 7, 816–823.
Gutiérrez-Corbo C, Alvarez-Velilla R, Reguera RM, García-Estrada C, Cushman M, Balana-Fouque R and Pérez-Perteiro Y (2019) Topoisomerase IB poisons induce histone H2A phosphorylation as a response to DNA damage in Leishmania infantum. International Journal for Parasitology: Drugs and Drug Resistance 19, 39–48.
Hart DT and Oppumedo FR (1984) The occurrence of glycosomes (microbo-
dules) in the promastigote stage of four major Leishmania species. Molecular and Biochemical Parasitology 13, 159–172.
He Y, Luo Y, Zhang D, Wang X, Zhang P, Li H, Ejaz S and Liang S (2019) PGK1-mediated cancer progression and drug resistance. American Journal of Cancer Research 9, 2280–2302.
Hevenker K, Verstak TA, Latat KE, Riggsbee DL and Mooney JW (2018) Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharmacologica Sinica 39, 844–861.
Hjørner E, Eghazhi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Ferro S, Palmieri C, Cavicchioli L, Zan GD, Aresa L and Benali S (2013) Leishmania amastigotes in neoplastic cells of 3 nonhistiocytic canine tumors. Veterinary Pathology 50, 749–752.
He Y, Luo Y, Zhang D, Wang X, Zhang P, Li H, Ejaz S and Liang S (2019) PGK1-mediated cancer progression and drug resistance. American Journal of Cancer Research 9, 2280–2302.
Hjørner K, Verstak TA, Latat KE, Riggsbee DL and Mooney JW (2018) Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharmacologica Sinica 39, 844–861.
Hjørner E, Eghazhi S, Carlson J, Stolt MF, Schedvins K, Johansson H, Shosman M and Avall-Lundqvist E (2013) HSP60 Predicts survival in advanced serous ovarian cancer. International Journal of Gynecologic Cancer 23, 448–455.
Ho MY, Tang SJ, Ng WV, Yang W, Leu SJJ, Lin YC, Feng CK, Sung JS and Sun KH (2010) Nucleotide-binding domain of phosphoglycerate kinase 1 reduces tumor growth by suppressing COX-2 expression. Cancer Science 101, 2411–2416.
Huang W, Barnes SM, Hajicek N, Hicks S, Harden TK, Sondek J and Zhang Q (2013) Small molecule inhibitors of phospholipase C from a novel high-throughput screen. Journal of Biological Chemistry 288, 5840–5848.
Hwang JW, Hong HY, Kim K, Kim SH, Choi YW, Kim MJ, Jung SH, Shim HJ, Bae WK and Hwang EC (2013) Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer. BMC Cancer 13, 431.
Ibanez E, Agliano A, Prior C, Ngeuwa P, Redrado M, Gonzalez-Zubeldia I, Palop D, Sanmartin C and Calvo A (2012) The quinoline
Kazemi-Rad E, Mohabadi M, Khadem-Erfan MB, Safaari M, Raoofian R, Hajjaran H, Hadighi R, Khamesipour A, Rezaie S and Abedikhojaste H (2013) Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Experimental Parasitology 135, 344–349.

Keithly JS and Fairlamb AH (1989) Inhibition of Leishmania species by α-difluoromethylornithine. Leishmaniasis 171, 749–756.

Keithly JS, Langreth SG, Buttle KF and Mannaella CA (2005) Electron tomographic and ultrastructural analysis of the Cryptosporidium parvum relict mitochondrion, its associated membranes, and organelles. Journal of Eukaryotic Microbiology 52, 132–140.

Khan S, Ince-Dunn G, Suomalainen A and Elo LL (2020) Integrative omics approaches provide biological and clinical insights: examples from mtochondrial diseases. The Journal of Clinical Investigation 130, 20–28.

Khosla TK, Zakharenko AI, Chepanova AA, Ilina ES, Zakharova OD, Kaledin VI, Nikolvin VP, Popova NA, Korchagina DV and Reynisson J (2020) Promising new inhibitors of tryosyl-DNA phosphodiesterase I (Tdp1) combining 4-arylcomarin and monoterpenoid moities as components of complex antitumor therapy. International Journal of Molecular Sciences 21, 126.

Koppaka V, Thompson DC, Chen Y, Taylor JS, Juvonen J, Pakkola V, Kumar R, Chauhan SB, Singh N, Faleiro RJ and Edwards CL (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum. In: Infectious Disorders-Drug Targets, 34, 195–202.

Koppaka V, Thompson DC, Chen Y, Taylor JS, Juvonen J, Pakkola V, Kumar R, Chauhan SB, Singh N, Faleiro RJ and Edwards CL (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum. In: Infectious Disorders-Drug Targets, 34, 195–202.
complexes which induce programmed cell death in the protozoan parasite Leishmania infantum. Journal of Inorgano Biochemistry 99, 727–736.

Nguewa PA, Villa TG and Notario V (2016) Microbiome control in the prevention and early management of cancer. In Villa T and Vinas M (eds), New Weapons to Control Bacterial Growth. Cham: Springer, pp. 219–237. https://doi.org/10.1007/978-3-319-28368-5_10.

Nicolas G, Ellena Koury DO, Salibi C, Nehme L, Mitri S, El Sayegh JSA, Rachd L and Khoury G (2018) Leishmania in a patient with small lymphocytic lymphoma/chronic lymphocytic leukemia. The American Journal of Case Reports 19, 512–516.

Nucci M and Anaiselle E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clinical Infectious Diseases 49, 1211–1225.

Nwee JA, Nwee El and Onoja US (2020) Nutrition, malnutrition, and leishmaniasis. Nutrition (Burbank, Los Angeles County, Calif.) 73, 110712.

Oberley LW and Buettner GR (1979) Role of superoxide dismutase in cancer: a review. Cancer Research 39, 1141–1149.

Oetken T, Hiscox B, Orengo I and Rosen T (2015) Cutaneous leishmaniasis mimicking squamous cell carcinoma. Dermatology Online Journal 23, 1–4.

Oppendoes FR and Szikora JP (2006) In silico prediction of the glycosomal enzymes of Leishmania major and trypanosomes. Molecular and Biochemical Parasitology 147, 193–206.

Palma LC, Ferreira LFGR, Petersen A, Dias BRS, de Menezes JPB, de Magalhães Moreira DR, Hernandes MZ and Veras PST (2019) A Docking-based structural analysis of geldanamycin-derived inhibitor binding to human or Leishmania HSP90. Scientific Reports 9, 1–9.

Paramchuk WJ, Ismail SO, Bhatia A and Gedamu L (2017) Cloning, characterisation and overexpression of two iron superoxide dismutase cDNAs from Leishmania chagasi: role in pathogenesis. Molecular and Biochemical Parasitology 209, 203–221.

Pereder J, Berioso B, Love Q, Loguidice N, Le TL, Harrelson JP and Roberts SC (2020) Critical functions of the polyamine putrescine for proliferation and viability of Leishmania donovani parasites. Amino Acids 52, 261–274.

Pérez-Pertejo Y, Escudero-Martínez JM, Reguera RM, Baláa-Fouche R, García PA, Jambrina PG, San Feliciano A and Castro MA (2019) Antileishmanial activity of terpenylquinolines on Leishmania infantum and their effects on Leishmania topoisoenzyme IB. International Journal for Parasitology: Drugs and Drug Resistance 11, 70–79.

Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Molecular Cancer Therapeutics 8, 2086–2095.

Perez JM, Fuertes MA, Nguewa PA, Castilla J and Alonso C (2008) Anticancer compounds as leishmanial drugs: challenges in chemother- apy and future perspectives. Current Medicinal Chemistry 15, 433–439.

Petersen A, Campos TA, Dantas D, Rebouças J, da Silva JC, de Menezes JP, Formiga FR, de Melo JV, Machado G and Veras PA (2018) Encapsulation of the HSP90 chaperone inhibitor 17-AAG in stable liposome allow increases in the therapeutic index as assessed, in vitro, on Leishmania (L) amazonensis amastigotes-hosted in mouse CBA macrophages. Frontiers in Cellular and Infection Microbiology 3, 303.

Pires VC, Magalhaes CP, Ferrante M, de Souza Rebouças J, Nguewa P, Severino P, Barral A, Veras PST and Formiga FR (2020) Solid lipid nanoparticles as a novel formulation approach for tansyepipir (17-AAG) against Leishmania infections: preparation, characterisation and macrophage uptake. Acta Tropicca 211, 105395.

Piro E, Kropp M, Cantaffa R, Lamberti AG, Carillio G and Molica S (2012) Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib. The Journal of Immunology 189, 703–715.

Pommier Y, Sun Y, Shar-yin NH and Nittis JL (2016) Roles of eukaryotic topoisoerases in transcription, replication and genomic stability. Nature Reviews Molecular Cell Biology 17, 703–721.

Ponte-Sucre A, Campos Y, Fernandez M, Moll H and Mendoza-León A (2019) Roles of eukaryotic topoisoerases in the development and viability of Leishmania donovani. Parasitology Research 86, 838–842.

Pusnik M, Charrrière F, Maser P, Waller RF, Dagley MJ, Lithgow T and Schneider A (2009) The single mitochondrial porin of Trypanosoma brucei is the main metabolite transporter in the outer mitochondrial membrane. Molecular Biology and Evolution 26, 671–680.

Ramazzotti G, Faenza I, Follo MI, Fiume R, Piazzì M, Giordano R, Fini M and Coco L (2011) Nuclear phospholipase C in biological control and cancer. Critical Reviews in Eukaryotic Gene Expression 21, 291–301.

Ramirez CA, Requena JM and Puerta CJ (2013) Alpha tubulin genes from Leishmania braziliensis: genomic organization, gene structure and insights on their expression. BMC Genomics 14, 454.

Ramos A, Munez E, Garcia-Dominguez J, Martinez-Rui R, Chicharro C, Banos I, Suarez-Massa D and Cuervas-Mons V (2015) Mucosal leishmaniasis mimicking squamous cell carcinoma in a liver transplant recipient. Transplant Infections Disease 17, 488–492.

Rashidi S, Mojtahedi Z, Shahriari B, Kalantar K and Hatam G (2019) An immunoprotective approach to identifying immunoreactive proteins in Leishmania infantum amastigotes using sera of dogs infected with canine visceral leishmaniasis. Pathogens and Global Health 113, 124–132.

Rashidi S, Nguewa P, Mojtahedi Z, Shahriari B, Kalantar K and Hatam G (2020a) Identification of immunoreactive proteins in secretions of Leishmania infantum promastigotes: an immunomoprotective approach. Frontiers in Immunology 11, 1554.

Rashidi S, Kalantar K, Nguewa P and Hatam G (2020b) Leishmanial selenoproteins and the host immune system: towards new therapeutic strategies? Transactions of The Royal Society of Tropical Medicine and Hygiene 114, 541–544.

Ray S, Sadhukhan PK, Mandal NB, Mahato SB and Majumder HK (1997) Dual inhibition of DNA topoisomerases of Leishmania donovani by novel indoly quinolines. Biochemical and Biophysical Research Communications 230, 171–175.

Ray S, Hazra B, Mittra B, Das A and Majumder HK (1998) Diospyrin, a bis-naphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani. Molecular Pharmacology 54, 994–999.

Reguera RM, Álvarez-Velilla R, Dominguez-Asejo B, Gutiérrez-Corbo C, Baláa-Fouche R, Cushman M and Pérez-Pertejo Y (2019) Antiparasitic effect of synthetic aromatethics on Leishmania infantum. BMC Veterinary Research 15, 405.

Reimão JQ, Mesquita JT, Ferreira DD and Tempone AG (2016) Investigation of calcium channel blockers as antiprotozoal agents and their interference in the metabolism of Leishmania (L) infantum. Evidence-Based Complementary and Alternative Medicine 2016, 1523691.

Requena JM, Montalvo AM and Fraga J (2015) Molecular chaperones of Leishmania: central players in many stress-related and unrelated physiological processes. BioMed Research International 2015, 301326.

Roy SK, Shrivastava A, Srivastav S, Shankar S and Srivastava RK (2020) SATB2 is a novel biomarker and therapeutic target for cancer. Journal of Cellular and Molecular Medicine 24, 11064–11069.

R Woodford M, Dunn DM, Cicarelli JG, Beeke K, Neckers L and Mollapour M (2016) Targeting HSP90 in non-cancerous malignancies. Current Topics in Medicinal Chemistry 16, 2792–2804.

Safarzadeh A, Alizadeh M, Beyranvand F, Jozaaee RF, Hajiasgharzadeh K, Baghbanzadeh A, Darakhshani A, Argentiero A, Baradaran B and Silvestris N (2020) Varied functions of immune checkpoints during cancer metastasis. Cancer Immunology, Immunotherapy 69, 1–20.

Sagar S, Kaur M, Minneman KP and Bajic VB (2010) Anti-cancer activities of dioxyspin, its derivatives and analogues. European Journal of Medicinal Chemistry 45, 3519–3530.

Saha S, Basu M, Guin S, Gupta P, Mitterstiller AM, Weiss G, Jana K and Ukil A (2019) Leishmania donovani exploits macrophage heme oxygenase-1 to neutralize oxidative burst and TLR signaling-dependent host defense. The Journal of Immunology 202, 827–840.

Sanchez-Moreno M, Gomez-Contreras F, Navarro P, Marin C, Ramirez-Macias I, Rosales M, Campayo L, Cano C, Sanz A and Yunta M (2015) 230 Imidaazole-containing phenothiazine derivatives inhibit Fe-SOD performance in Leishmania species and are active in vitro against visceral and mucosal leishmaniasis. Parasitology 142, 1115–1129.

Sarkar D, Leung EY, Baguley BC, Finlay GJ and Askanian-Amiri ME (2015) Epigenetic regulation in human melanoma: past and future. Epigenetics 10, 103–121.

Sauter IP, Madrid KG, de Assis JB, Sá-Nunes A, Torrecilhas AC, Staquicini DI, Pasqualini R, Arap W and Cortez M (2019) TLK9/MyD88/TRIF
Sengupta T, Mukherjee M, Das A, Mandal C, Das R, Mukherjee T and Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ, Hickman M, Sett R, Basu N, Ghosh AK and Das PK (2006) The anti-cancer therapeutics. Frontiers in Oncology 36, 151354.

Sharma M and Multhoff G (2007) Heat shock proteins in cancer. Annals of the New York Academy of Sciences 1113, 192–201.

Shoshan-Barmatz V, Krelin Y, Shteinfer-Kuzmine A and Arif T (2019) Bioactivatable drug, α-lapachone, alters the redox state of NQO1 + pancreatitis, causing perturbation in central carbon metabolism. Journal of Biological Chemistry 292, 18203–18216.

Singh G and Dey CS (2007) Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovani. Acta Tropica 103, 172–185.

Singh G, Thakur M, Chakraborti PK and Dey CS (2009) Evidence for the presence of R205G mutation at the ATPase domain of topoisomerase II in an arsenite-resistant Leishmania donovani exhibiting a differential drug inhibition profile. International Journal of Antimicrobial Agents 33, 80–85.

Slutn KM, Grace JM, Macdonald TL and Pearson RD (1996) Effect of mitochondrial analogs on topoisomerase II of Leishmania chagasi. Antimicrobial Agents and Chemotherapy 40, 706–709.

Son S, Anand P and Padwad YS (2019) MAPKAPK2: the master regulator of RNA-binding protein modules transcript stability and tumor progression. Journal of Experimental & Clinical Cancer Research 38, 121.

Souza-Silva F, Bourguignon SC, Pereira BAS, de Castro Cortes LM, de Oliveira LFG, Henrique-Pons A, Finkelstein LC, Ferreira VF, Carneiro PF and de Pinho RT (2015) Epoxy-α-lapachone has in vitro and in vivo anti-Leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite. Antimicrobial Agents and Chemotherapy 59, 1910–1918.

Spadaro F, Ramoni C, Mezzannicca D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S and Podo F (2008) Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Research 68, 6541–6549.

Sprooten J, Agostinis P and Garg AD (2019) Type I interferons and dendritic cells in cancer immunotherapy. International Review of Cell and Molecular Biology 348, 217–265.

Stevens M, Abdeen S, Salim N, Ray AM, Washburn A, Chitre S, Sivinski J, Park Y, Hoang QQ and Chapman E (2019) HSPOP10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules. Bioorganic & Medicinal Chemistry Letters 29, 1106–1112.

Su TR, Lin JJ, Chiu CC, Chen JYF, Su JH, Cheng CJ, Hwang HI and Wu YJ (2012) Proteomic investigation of anti-tumor activities exerted by larvicide in A. 2058 melanoma cells. Electrophoresis 33, 1139–1152.

Sun Y, Liu Z, Zou X, Lan Y, Sun X, Wang X, Zhao S, Jiang C and Liu H (2015) Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer. Journal of Bioenergetics and Biomembranes 47, 319–329.

Sundar S and Olliaro PL (2007) Milestones in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Therapeutics and Clinical Risk Management 3, 733.

Syo G-D, Dunn J and Zhu H (2020) Developments and applications of functional NQO1 protein. Microarrays Molecular & Cellular Proteomics 19, 916–927.

Tandon R, Chandra S, Baharia RK, Das S, Misra P, Kumar A, Siddiqi MI, Sundar S and Dube A (2014) Characterization of the proliferating cell nuclear antigen of Leishmania donovani clinical isolates and its association with antimony resistance. Antimicrobial Agents and Chemotherapy 58, 2997–3007.

Tang SJ, Ho MY, Cho HC, Lin YC, Sun GH, Chi KH, Wang YS, Jouh RS, Yang W and Xu-AI (2008) Phosphoglycerate kinase 1-overexpressing lular cancer cells reduce cyclooxygenase 2 expression and promote anti-tumor immunity in vivo. International Journal of Cancer 123, 2840–2848.

Tataranni T and Piccoli C (2019) Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxidative Medicine and Cellular Longevity 2019, 1–14.

Thompson MD and Monga SP (2007) WNT/B-catenin signaling in liver health and disease. Hepatology 45, 1298–1305.

Toogeh G, Shirkoohi R, Nickbin M, Najafi S, Salimi M, Farsi L and Ferdowski S (2016) Visceral leishmaniasis presented as myelofibrosis and low grade lymphoma in a sporadic region of Iran, report a rare case. International Journal of Hematology-Oncology and Stem Cell Research 4, 36–39.

Torre LA, Siegel RL, Feron V, DeSantis CE, Jemal A and Wind ME (2015) Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiology and Prevention Biomarkers 25, 16–27.

Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J and Arenas R (2017) Leishmaniasis: a review. F1000Research 6, 750.

Torti F, Pulini S, Morelli AM, Bacci F and Di Bartolomeo P (2015) Visceral leishmaniasis in relapsed and treated multiple myeloma in the era of high dose and ‘novel agent’ therapy. International Journal of Hematology 102, 391–393.

Tretina K, Gotia HT, Mann DJ and Silva JC (2015) Theileria-transformed bovine leukocytes have cancer hallmarks. Trends in Parasitology 31, 306–314.

Tsai YP, Yang MH, Huang CH, Chang SY, Chen PM, Liu CJ, Teng SC and Wu KJ (2009) Interaction between HSPOP1 and β-catenin promotes metastases. Cancerogenesis 30, 1049–1057.

Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T and Graefen M, Huland H, Salomon G and Steuber T (2015) BCL-2–tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEEN deletion. The American Journal of Pathology 184, 659–671.

Tuujii M and DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493–501.

Tuujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93, 705–716.

Umejeiog NN, Gollapalli D, Shirling L, Vollfson A, Lu J, Benjamin NN, Stroupe AH, Riera TV, Striepen B and Hedstrom L (2008) Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis. Chemistry & Biology 15, 70–77.
Van Assche T, Deschacht M, da Luz RAI, Maes L and Cos P (2011) Leishmania-macrophage interactions: insights into the redox biology. Free Radical Biology and Medicine 51, 337–351.

Vasconcelos G, Azevedo-Silva F, Thuler L, Pina ETG, Souza CS, Calabrese K and Pombo-de-Oliveira MS (2014) The concurrent occurrence of Leishmania chagasi infection and childhood acute leukemia in Brazil. Revista Brasileira de Hematologia e Hemoterapia 36, 356–362.

Vassalli G (2019) Alddehyde dehydrogenases: not just markers, but functional regulators of stem cells. Stem Cells International 2019, 3904645.

Viana AG, Magalhães LMD, Giunchetti RC, Dutra WO and Gollob KJ (2019) Leishmania infantum induces expression of the negative regulatory checkpoint, CTLA-4, by human naïve CD8+ T cells. Parasite Immunology 41, e12659.

Vieira L, Lavan A, Dagger F and Cabantchik Z (1994) The role of anions in pH regulation of Leishmania major promastigotes. Journal of Biological Chemistry 269, 16254–16259.

Watson HC and Littlechild JA (1990) Isoenzymes of phosphoglycerate kinase: evolutionary conservation of the structure of this glycolytic enzyme. Biochemical Society Transactions 18, 187–190.

Willson M, Callens M, Kuntz DA, Perie J and Opperdoes FR (1993) Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Molecular and Biochemical Parasitology 59, 201–210.

Wood L, Leese MP, Leblond B, Woo L, Ganeshapillai D, Purohit A, Reed MJ, Potter BV and Packham G (2001) Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. Anti-Cancer Drug Design 16, 209–215.

Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA and Neamati N (2012) Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences 109, 16348–16353.

Xu S, Sankar S and Neamati N (2014) Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today 19, 222–240.

Yamashita M, Tahara T, Hayakawa S, Matsumoto H, Wada S-I, Tomioka K and Iida A (2018) Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-targeted inhibitors. Bioorganic & Medicinal Chemistry 26, 1920–1928.

Yan J, Guo Y, Wang Y, Mao F, Huang L and Li X (2015) Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents. European Journal of Medicinal Chemistry 95, 220–229.

Yang W, Shin H-Y, Cho H, Chung J-Y, Lee E-j, Kim J-H and Kang E-S (2020) TOM40 inhibits ovarian cancer cell growth by modulating mitochondrial function including intracellular ATP and ROS levels. Cancers 12, 1329.

You BR and Park WH (2016) Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion. Oncology Reports 35, 546–551.

Younus H (2018) Therapeutic potentials of superoxide dismutase. International Journal of Health Sciences 12, 88.

Zarsky V, Tachezy J and Dolezal P (2012) TOM40 is likely common to all mitochondria. Current Biology 22, R479–R481.

Zigmond E, Ya’acov AB, Lee H, Lichtenstein Y, Shalev Z, Smith Y, Zolotarov L, Ziv E, Kalman R and Le HV (2015) Suppression of hepatocellular carcinoma by inhibition of overexpressed ornithine aminotransferase. ACS Medicinal Chemistry Letters 6, 840–844.

Zininga T and Shonhai A (2019) Small molecule inhibitors targeting the heat shock protein system of human obligate protozoan parasites. International Journal of Molecular Sciences 20, 5930.